Table 1. Cohort description of antiretroviral therapy-treated adults eligible for inclusion in analysis for 60 months of follow-up after antiretroviral therapy initiation.
| 83 926 initiated ART (of whom 3083 with less than drugs were excluded) |
|||||
|---|---|---|---|---|---|
| Follow-up time (months) | In care | LTFUa | In care without a CD4+ cell countb | In care with CD4+ cell countc | In care with pre-ART CD4+ and follow-up CD4+ cell countd |
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| 0 | 80 843 | ||||
| 6 | 65 930 (82) | 14 913 (18) | 13 851 (21) | 29 050 (44) | 23 029 (35) |
| 12 | 54 923 (68) | 25 920 (32) | 15 316 (28) | 22 347 (41) | 17 260 (31) |
| 24 | 39 547 (49) | 15 376 (19) | 15 257 (39) | 14 058 (36) | 10 232 (26) |
| 36 | 26 675 (33) | 12 872 (16) | 16 192 (61) | 6037 (23) | 4446 (17) |
| 48 | 18 322 (23) | 8353 (10) | 13 245 (72) | 2024 (11) | 3053 (17) |
| 60 | 10 423 (13) | 7899 (9) | 6712 (64) | 2149 (21) | 1562 (15) |
ART, antiretroviral therapy; LTFU, loss to follow-up.
a
LTFU (individuals who have not had a clinic visit for 6 months and were excluded from the analyses) the percentage is among all patients initiated on three-drug first-line ART regimen.
b
Patients in care without a CD4+ cell count within 2 months of time point, excluded from the analyses. The percentage is among all patients in care at each time point.
c
Patients in care with CD4+ cell counts within 2 months of time point, the percentage is among all patients in care at each time point.
d
Patients in care with pre-ART CD4+ cell and a follow-up CD4+ cell count, the percentage is among all patients in care at each time point.